Literature DB >> 2472359

Neuropeptide Y and galanin in norepinephrine release in hypothalamic slices.

K Tsuda1, H Yokoo, M Goldstein.   

Abstract

Noradrenergic neurons in the locus ceruleus contain neuropeptide Y and galanin, which project to the hypothalamic region. We have investigated the regulatory mechanisms of these peptides on norepinephrine release in rat hypothalamic slices in vitro. Neuropeptide Y and galanin significantly inhibited the stimulation-evoked [3H]norepinephrine release in a dose-dependent manner (1 Hz: S2/S1 ratio (mean +/- SEM), control 0.947 +/- 0.040, n = 11, neuropeptide Y 1 x 10(-8) M 0.509 +/- 0.013, n = 8, p less than 0.01, neuropeptide Y 1 x 10(-7) M 0.283 +/- 0.021, n = 8, p less than 0.01; galanin 1 x 10(-7) M 0.448 +/- 0.026, n = 8, p less than 0.01, galanin 1 x 10(-6) M 0.261 +/- 0.023, n = 8, p less than 0.01). The inhibition of norepinephrine release by the alpha-2 agonist UK 14,304 was potentiated by neuropeptide Y and galanin. The blockade of the alpha 2-adrenergic receptors by RX 781094 diminished the inhibitory effects of neuropeptide Y and galanin on norepinephrine release. Pretreatment of hypothalamic slices with islet activating protein (a toxin that interferes with the coupling of inhibitory receptors to adenylate cyclase) attenuated the suppression of norepinephrine release by UK 14,304, neuropeptide Y, and galanin. These results support the idea that neuropeptide Y and galanin are involved in the regulation of central adrenergic transmission partially mediated by alpha 2-adrenergic receptors and islet-activating protein-sensitive guanosine triphosphate-binding proteins in rat hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472359     DOI: 10.1161/01.hyp.14.1.81

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

1.  Enhanced hippocampal noradrenaline and serotonin release in galanin-overexpressing mice after repeated forced swimming test.

Authors:  Takashi Yoshitake; Fu-Hua Wang; Eugenia Kuteeva; Kristina Holmberg; Masatoshi Yamaguchi; Jacqueline N Crawley; Robert Steiner; Tamas Bartfai; Sven Ove Ogren; Tomas Hökfelt; Jan Kehr
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-30       Impact factor: 11.205

2.  Galanin receptor-mediated inhibition of glutamate release in the arcuate nucleus of the hypothalamus.

Authors:  G A Kinney; P J Emmerson; R J Miller
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

3.  Genetic comparison of seizure control by norepinephrine and neuropeptide Y.

Authors:  D Weinshenker; P Szot; N S Miller; N C Rust; J G Hohmann; U Pyati; S S White; R D Palmiter
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

4.  Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice.

Authors:  Andrew Holmes; Rebecca J Yang; Jacqueline N Crawley
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

Review 5.  Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.

Authors:  Sven Ove Ogren; Eugenia Kuteeva; Tomas Hökfelt; Jan Kehr
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity.

Authors:  C K Boughton; K G Murphy
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

7.  Changes in chemical coding of sympathetic chain ganglia (SChG) neurons supplying porcine urinary bladder after botulinum toxin (BTX) treatment.

Authors:  E Lepiarczyk; A Bossowska; M Majewski
Journal:  Cell Tissue Res       Date:  2015-01-27       Impact factor: 5.249

Review 8.  The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease.

Authors:  Billie J Matchett; Lea T Grinberg; Panos Theofilas; Melissa E Murray
Journal:  Acta Neuropathol       Date:  2021-01-11       Impact factor: 17.088

9.  Renin-Angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension.

Authors:  Kazushi Tsuda
Journal:  Int J Hypertens       Date:  2012-11-21       Impact factor: 2.420

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.